Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,219 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 4,219 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $3.03, for a total value of $12,783.57. Following the sale, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $646,338.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Trevi Therapeutics Stock Up 5.8 %

Shares of Trevi Therapeutics stock traded up $0.17 during mid-day trading on Monday, hitting $3.12. The stock had a trading volume of 480,262 shares, compared to its average volume of 236,037. The firm has a 50-day moving average of $2.87 and a two-hundred day moving average of $2.87. The firm has a market cap of $219.76 million, a P/E ratio of -9.18 and a beta of 0.96. Trevi Therapeutics, Inc. has a 12-month low of $0.97 and a 12-month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the prior year, the business earned ($0.07) earnings per share. Sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Institutional Trading of Trevi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its position in shares of Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after acquiring an additional 11,450 shares during the last quarter. Logos Global Management LP boosted its position in shares of Trevi Therapeutics by 27.3% during the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares during the period. Ally Bridge Group NY LLC acquired a new stake in Trevi Therapeutics in the 2nd quarter valued at approximately $4,395,000. Hsbc Holdings PLC purchased a new stake in Trevi Therapeutics in the second quarter valued at approximately $61,000. Finally, Dimensional Fund Advisors LP lifted its stake in Trevi Therapeutics by 217.6% during the second quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock worth $215,000 after purchasing an additional 49,475 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TRVI shares. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a research report on Monday. They issued an “outperform” rating and a $7.00 target price for the company. Raymond James assumed coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price objective for the company. HC Wainwright started coverage on Trevi Therapeutics in a report on Friday, August 30th. They set a “buy” rating and a $6.00 target price on the stock. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Finally, Rodman & Renshaw initiated coverage on Trevi Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $7.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Trevi Therapeutics has an average rating of “Buy” and a consensus target price of $7.67.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.